Cargando…

Phase 1 study on docetaxel and ifosfamide in patients with advanced solid tumours

Detalles Bibliográficos
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1998
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150076/

Ejemplares similares

Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours.
por: Pronk, L. C., et al.
Publicado: (1998)

Phase I study of docetaxel plus ifosfamide in patients with advanced cancer
por: Marx, G, et al.
Publicado: (2002)

Phase I–II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer
por: Kosmas, C, et al.
Publicado: (2003)

Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours
por: Kosmas, C, et al.
Publicado: (2000)

Possible metabolic interaction between docetaxel and ifosfamide
por: Ando, Y
Publicado: (2000)

Cyclosporin A and doxorubicin-ifosfamide in resistant solid tumours: a phase I and an immunological study.
por: González-Manzano, R., et al.
Publicado: (1995)

A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours
por: Bowles, D W, et al.
Publicado: (2013)

A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours
por: Pronk, L C, et al.
Publicado: (2000)

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours
por: Martin, L P, et al.
Publicado: (2012)

Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours
por: Freyer, G, et al.
Publicado: (2012)

Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies
por: Hamberg, P, et al.
Publicado: (2010)

A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours
por: Attard, G, et al.
Publicado: (2007)

A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours
por: Blagden, S P, et al.
Publicado: (2008)

A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours
por: Eskens, F A L M, et al.
Publicado: (2014)

Phase I study of aflibercept in combination with docetaxel in Japanese patients with advanced solid malignancies
por: Sunakawa, Yu, et al.
Publicado: (2022)

PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours
por: McKeage, Mark J, et al.
Publicado: (2012)

Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours
por: Lickliter, Jason D., et al.
Publicado: (2021)

A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours
por: Ang, Yvonne L. E., et al.
Publicado: (2020)

Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study
por: Robert, Francisco, et al.
Publicado: (2009)

Correction: Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study
Publicado: (2020)

A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
por: LoRusso, Patricia M., et al.
Publicado: (2017)

Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306
por: Tanaka, Kazuhiro, et al.
Publicado: (2022)

Paclitaxel–ifosfamide–carboplatin combination chemotherapy regimen in advanced uterine and adnexal malignant mixed Mullerian tumours
por: Kosmas, C, et al.
Publicado: (2011)

A Phase II Study of Docetaxel in Patients with Relapsed and Refractory Ewing's Tumours
por: Meyer, T., et al.
Publicado: (2003)

Ifosfamide nephrotoxicity in adult patients
por: Ensergueix, Gaël, et al.
Publicado: (2019)

Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer
por: Yamaguchi, K, et al.
Publicado: (2006)

Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours
por: Bahleda, Rastislav, et al.
Publicado: (2015)

Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours
por: Shapiro, Geoffrey I., et al.
Publicado: (2021)

Neoadjuvant docetaxel, cisplatin and ifosfamide (ITP) combination chemotherapy for treating penile squamous cell carcinoma patients with terminal lymph node metastasis
por: Xu, Jian, et al.
Publicado: (2019)

The growing pains of ifosfamide
por: Sprangers, Ben, et al.
Publicado: (2020)

Correction to: Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC
por: Frampton, James E.
Publicado: (2021)

Phase I trial outcomes in older patients with advanced solid tumours
por: Khan, K H, et al.
Publicado: (2016)

A New Method to Quantify Ifosfamide Blood Levels Using Dried Blood Spots and UPLC-MS/MS in Paediatric Patients with Embryonic Solid Tumours
por: Torres, Luz-María, et al.
Publicado: (2015)

Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide
por: Chawla, Sant P, et al.
Publicado: (2013)

Ifosfamide ±VP16 in Childhood' Malignancy: A Phase II (toxicity) Study
por: Pizer, B., et al.
Publicado: (1988)

Pharmacokinetic Study of Perioperative Intravenous Ifosfamide
por: Van der Speeten, Kurt, et al.
Publicado: (2011)

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
por: Molife, L Rhoda, et al.
Publicado: (2014)

Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors
por: Awada, A. H., et al.
Publicado: (2012)

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours
por: Berlin, Jordan, et al.
Publicado: (2018)

Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial
por: Qin, Shukui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ie68por29uj265io3gffgiqbud